Swedish and international investors acquire 2 million shares in Hansa Medical AB from Farstorps Gård AB

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, AUSTRALIA, CANADA, SWITZERLAND, SOUTH AFRICA, SINGAPORE, HONG
KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION
OR RELEASE WOULD BE UNLAWFUL
Stockholm, December 8, 2015 – Hansa Medical AB (publ) ("Hansa Medical") has been
informed that Farstorps Gård AB has sold 2 million shares in Hansa Medical
through an accelerated bookbuilding to Swedish and international investors at a
price of SEK 26,25 per share. Also, Hansa Medical’s CEO Göran Arvidson acquired
30,000 shares in the transaction, which means that his holding now amounts to
63,000 shares.

ABG Sundal Collier AB, Carnegie Investment Bank AB and Erik Penser
Bankaktiebolag acted as Joint Bookrunners in connection with the placing.

The information in this press release is disclosed pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was released for public disclosure on December 8, 2015 at 08.30 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory
enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Other projects include HBP (a market introduced diagnostic marker for severe
sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical
development). The company is based in Lund, Sweden. Hansa Medical's share
(ticker: HMED) is listed on Nasdaq Stockholm.